We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Drugmakers who redact commercially confidential information from clinical study reports in Europe will have to justify their actions, says a spokesman for the European Medicines Agency, explaining what categories of confidential information the redacted data fall under. Read More
The FDA now has the power to stop any pharmaceutical import it suspects could be adulterated or misbranded, according to a final rule that implements the agency’s new import authority. Read More
Boehringer Ingelheim (BI) will spend $650 million to settle approximately 4,000 state and federal lawsuits alleging the drugmaker didn’t do enough to warn patients about the hazards of its blockbuster blood thinner Pradaxa. Read More
The FDA wants to know what effect distractions such as moving visuals and music may have on patients’ retention of risk information in direct-to-consumer drug advertisements. Read More
GlaxoSmithKline is facing another bribery probe, this time from a UK watchdog that plans to investigate the drugmaker’s business practices around the world. Read More
Drugmakers should evaluate potential names for new drugs and weed out candidates that include elements such as medical abbreviations, inactive ingredients and partial lists of active ingredients, the FDA says. Read More
Novartis wants the FDA to back off plans that would require drugmakers to include details of clinical trials data in labeling for drugs brought to market under accelerated approval pathways. Read More
Both sides in a patent lawsuit involving the drug Suprep are asking a federal appeals court to reconsider its opinion in the case, saying the court set a dangerous precedent for future Hatch-Waxman patent suits because it recognized infringement for unapproved uses and clouds the definition of “patient” when it comes to the patent claim. Read More